MedTrace Logo

ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease

NCT04899518 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 922

Last updated 2023-03-16

No results posted yet for this study

Summary

Study Evaluating the Safety and Efficacy of Two Concentrations (0.4% and 1%) of ALY688 Ophthalmic Solution in Subjects with Dry Eye Disease

Conditions

  • Dry Eye

Interventions

DRUG

ALY688 Ophthalmic Solution

Ophthalmic Solution

Sponsors & Collaborators

  • Allysta Pharmaceutical

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-19
Primary Completion
2023-03-14
Completion
2023-03-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04899518 on ClinicalTrials.gov